Patents by Inventor Edwin Katibah
Edwin Katibah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210246122Abstract: The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: ApplicationFiled: June 14, 2019Publication date: August 12, 2021Applicant: Aduro Biotech, Inc.Inventors: George Edwin Katibah, Jung Yun Kim, Chudi Obioma Ndubaku, Meiliana Tjandra, Tucker Curran Roberts
-
Patent number: 11040053Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: GrantFiled: October 21, 2019Date of Patent: June 22, 2021Assignee: CHINOOK THERAPEUTICS, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
-
Patent number: 10906930Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.Type: GrantFiled: October 28, 2016Date of Patent: February 2, 2021Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AGInventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Jeffrey McKenna, Stephen M. Canham, Chudi Obioma Ndubaku
-
Patent number: 10738056Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: GrantFiled: September 14, 2018Date of Patent: August 11, 2020Assignee: Aduro BioTech Inc.Inventors: Chudi Obioma Ndubaku, George Edwin Katibah, Tucker Curran Roberts, Leonard Sung, Stephane Ciblat, Franck Raeppel, Vu Linh Ly, Yeeman K. Ramtohul, Taras Rybak, Mariam Zaky, Laura Gillard, Hossein Ismaili
-
Publication number: 20200179431Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: ApplicationFiled: October 21, 2019Publication date: June 11, 2020Applicant: ADURO BIOTECH, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, JR.
-
Patent number: 10449211Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: GrantFiled: March 9, 2016Date of Patent: October 22, 2019Assignee: ADURO BIOTECH, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
-
Publication number: 20190119285Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: ApplicationFiled: September 14, 2018Publication date: April 25, 2019Inventors: Chudi Obioma NDUBAKU, George Edwin KATIBAH, Tucker Curran ROBERTS, Leonard SUNG, Stephane CIBLAT, Franck RAEPPEL, Vu Linh LY, Yeeman K. RAMTOHUL, Taras RYBAK, Mariam ZAKY, Laura GILLARD, Hossein ISMAILI
-
Publication number: 20190062365Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.Type: ApplicationFiled: October 28, 2016Publication date: February 28, 2019Applicants: ADURO BIOTECH, INC., NOVARTIS AGInventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Kelsey GAUTHIER, Laura Hix GLICKMAN, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, Jr., Jeffrey McKENNA, Stephen M. CANHAM, Chudi Obioma NDUBAKU
-
Publication number: 20180369268Abstract: The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases.Type: ApplicationFiled: December 16, 2016Publication date: December 27, 2018Applicant: ADURO BIOTECH, INC.Inventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, JR.
-
Publication number: 20180064745Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: ApplicationFiled: March 9, 2016Publication date: March 8, 2018Applicant: ADURO BIOTECH, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
-
Patent number: 8296343Abstract: Disclosed is a system and program for processing temporal data. A spatial query is received specifying a mapping function that identifies a set of temporal values for one or more objects. Geographic positions are automatically extracted from each set of temporal values for each of the one or more objects. Point objects are generated from the geographic positions. One or more spatial objects are generated from the point objects.Type: GrantFiled: September 9, 2008Date of Patent: October 23, 2012Assignee: International Business Machines CorporationInventors: Edwin Katibah, Martin Siegenthaler
-
Publication number: 20090012994Abstract: Disclosed is a system and program for processing temporal data. A spatial query is received specifying a mapping function that identifies a set of temporal values for one or more objects. Geographic positions are automatically extracted from each set of temporal values for each of the one or more objects. Point objects are generated from the geographic positions. One or more spatial objects are generated from the point objects.Type: ApplicationFiled: September 9, 2008Publication date: January 8, 2009Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Edwin Katibah, Martin Siegenthaler
-
Patent number: 7472109Abstract: Disclosed is a method for processing temporal data. A spatial query is received specifying a mapping function that identifies a set of temporal values for one or more objects. Geographic positions are automatically extracted from each set of temporal values for each of the one or more objects. Point objects are generated from the geographic positions. One or more spatial objects are generated from the point objects.Type: GrantFiled: December 30, 2002Date of Patent: December 30, 2008Assignee: International Business Machines CorporationInventors: Edwin Katibah, Martin Siegenthaler
-
Publication number: 20040128314Abstract: Disclosed is a method, system, and program for processing temporal data. A spatial query is received specifying a mapping function that identifies a set of temporal values for one or more objects. Geographic positions are automatically extracted from each set of temporal values for each of the one or more objects. Point objects are generated from the geographic positions. One or more spatial objects are generated from the point objects.Type: ApplicationFiled: December 30, 2002Publication date: July 1, 2004Applicant: International Business Machines CorporationInventors: Edwin Katibah, Martin Siegenthaler